Research Article
Albuterol Use in Children Hospitalized with Human Metapneumovirus Respiratory Infection
Table 2
Characteristics of patients hospitalized with human metapneumovirus infection stratified by receipt of albuterol.
| Characteristic | Albuterol () | No albuterol () | value | Number (%) | Number (%) |
| Age (months) | 18 (IQR 9–46) | 15 (IQR 6–44) | 0.29 | Female gender | 49 (35%) | 33 (51%) | 0.03 | CMC (nonasthma) | 42 (30%) | 12 (18%) | 0.09 | CMC (asthma) | 60 (42%) | 4 (6%) | <0.001 | Admission diagnosis | | | <0.001 | Asthma exacerbation | 28 (20%) | 0 | | Acute respiratory infection | 101 (71%) | 43 (66%) | | Seizure | 3 (2%) | 3 (5%) | | Vaso-occlusive crisis | 6 (4%) | 2 (3%) | | Other | 4 (3%) | 17 (26%) | | Supplemental oxygen | 94 (66%) | 20 (31%) | <0.001 | Hospital LOS (days) | 3 (IQR 2–5) | 3 (IQR 2–5) | 0.18 | Viral coinfection | 30 (21%) | 13 (20%) | 0.85 | Mortality | 4 (3%) | 0 | 0.31 |
|
|
IQR: interquartile range; CMC: chronic medical condition; LOS: length of stay.
|